We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Milford, Massachusetts-based Waters Corporation (WAT - Free Report) is a prominent medical instrument supplying firm, conducting trade in the healthcare sector. The company is renowned analytical instrument producer but also builds up and supplies software-based products to its customers.
WAT’s global pharmaceuticals business, its largest single market and major revenue driver, is the company’s major profit churner fuelling its growth. The company’s solid market presence in both high-performance liquid chromatography market and mass spectrometry markets, strength in regulated testing, non-discretionary product demand are its staple growth drivers.
Also, the company’s robust product portfolio supplements its strength. Thriving life sciences and analytical instrument markets, accelerated drug approvals by the FDA and favorable funding environment bode well for the company’s future growth.
Despite the positives, Waters’ rising debt levels and the consequent interest expenses remain a burden, given its recent acquisitions. Also, increasing R&D expenses and volatility in client spending add to the company’s woes.
We have highlighted some of the key details from the just-released announcement below:
Earnings: Waters’ adjusted earnings from continuing operations came in at $1.59 per share, which beat the Zacks Consensus Estimate by four cents.
Sales: Sales of $531 million lagged the Zacks Consensus Estimate of $533 million but grew 6.6% on a year-over-year basis.
Key Stats: Recurring revenues, which represent the combination of service and precision chemistries revenues, increased 6% on a constant currency basis.
Stock Price: Shares prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this WAT earnings report later!
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Waters Corp (WAT) Earnings Beat Estimates in Q1
Milford, Massachusetts-based Waters Corporation (WAT - Free Report) is a prominent medical instrument supplying firm, conducting trade in the healthcare sector. The company is renowned analytical instrument producer but also builds up and supplies software-based products to its customers.
WAT’s global pharmaceuticals business, its largest single market and major revenue driver, is the company’s major profit churner fuelling its growth. The company’s solid market presence in both high-performance liquid chromatography market and mass spectrometry markets, strength in regulated testing, non-discretionary product demand are its staple growth drivers.
Also, the company’s robust product portfolio supplements its strength. Thriving life sciences and analytical instrument markets, accelerated drug approvals by the FDA and favorable funding environment bode well for the company’s future growth.
Despite the positives, Waters’ rising debt levels and the consequent interest expenses remain a burden, given its recent acquisitions. Also, increasing R&D expenses and volatility in client spending add to the company’s woes.
Zacks Rank: Currently, Waters has a Zacks Rank #2 (Buy) but that could change following its first-quarter 2018 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
We have highlighted some of the key details from the just-released announcement below:
Earnings: Waters’ adjusted earnings from continuing operations came in at $1.59 per share, which beat the Zacks Consensus Estimate by four cents.
Sales: Sales of $531 million lagged the Zacks Consensus Estimate of $533 million but grew 6.6% on a year-over-year basis.
Key Stats: Recurring revenues, which represent the combination of service and precision chemistries revenues, increased 6% on a constant currency basis.
Stock Price: Shares prices did not show any movement in the pre-market trading session.
Waters Corporation Price
Waters Corporation Price | Waters Corporation Quote
Check back later for our full write up on this WAT earnings report later!
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>